164
Citations
76
Journals
2015
First Cited
2022
Last Cited

Articles citing This Document (Page 1 of 4)

ArticleJournalYear
Systematic Review on the Use of Biosimilars of Trastuzumab in HER2+ Breast Cancer2022
Non-Medical Switching in Dermatology: Cost-Conscious Policy or an Affront to Patient Safety?
Under the Umbrella of Clinical Pharmacology: Inflammatory Bowel Disease, Infliximab and Adalimumab, and a Bridge to an Era of Biosimilars2022
Statistical Aspects of Bioanalytical Testing2022
No two classes of biosimilars: Urgent advice to the US Congress and the FDAJournal of Clinical Pharmacy and Therapeutics
DataSheet_1.docx2020
table_2.PDF2018
table_1.PDF2018
image_2.PDF2018
image_1.PDF2018
Long-Term Safety and Effectiveness of PF-05280014 (a Trastuzumab Biosimilar) Treatment in Patients with HER2-Positive Metastatic Breast Cancer: Updated Results of a Randomized, Double-Blind Study.BioDrugs2022
Long-term data on the proposed adalimumab biosimilar BCD-057 in patients with moderate to severe psoriasis: A randomized controlled trial.PLoS ONE2022
Physicochemical stability of PF-05280014 (trastuzumab-qyyp; Trazimera), a trastuzumab biosimilar, under extended in-use conditions.Journal of Oncology Pharmacy Practice2022
Interchangeability of biosimilars: A study of expert views and visions regarding the science and substitution.PLoS ONE2022
Biosimilars2018
Application of an Adaptive Analytical Characterization Strategy to Support Development and Approval of BiosimilarsAAPS Advances in the Pharmaceutical Sciences Series2018
Switching between reference adalimumab and biosimilars in chronic immune-mediated inflammatory diseases: A systematic literature reviewBritish Journal of Clinical Pharmacology2021
BIOSIMILARS IN RHEUMATOLOGYNauchno-Prakticheskaya Revmatologiya2017
Policies for biosimilar uptake in Europe: An overviewPLoS ONE2017
Arzneimittelverordnungen nach Regionen2017
Arzneiverordnungen 2016 im Überblick2017
Pharmacovigilance of Biosimilars: Global Experience and PerspectiveAAPS Advances in the Pharmaceutical Sciences Series2018
The Expiry of Humira Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy MeasuresFrontiers in Pharmacology2020
A Randomized, Double-Blind, Single-Dose Study Comparing the Biosimilarity of HOT-1010 With Bevacizumab (Avastin®) in Chinese Healthy Male SubjectsFrontiers in Pharmacology2021
Cost evolution of biological drugs in rheumatoid arthritis patients in a tertiary hospital: Influential factors on priceReumatología Clínica (English Edition)2021
Cost evolution of biological drugs in rheumatoid arthritis patients in a tertiary hospital: Influential factors on priceReumatología Clínica2021
Factors Influencing Infusion-Related Reactions Following Dosing of Reference Rituximab and PF-05280586, a Rituximab BiosimilarBioDrugs2021
Efficacy and safety of LY2963016 insulin glargine versus insulin glargine (Lantus) in Chinese adults with type 2 diabetes: A phase III, randomized, open-label, controlled trialDiabetes, Obesity and Metabolism2021
A Biosimilarity Study Between QX001S and Ustekinumab in Healthy Chinese Male SubjectsFrontiers in Pharmacology2021
Evolving Biosimilar Clinical Requirements: A Qualitative Interview Study with Industry Experts and European National Medicines Agency RegulatorsBioDrugs2021
A Phase I, Randomized, Single-Dose Study to Evaluate the Biosimilarity of HOT-3010 to Adalimumab Among Healthy Chinese Male SubjectsFrontiers in Pharmacology2021
Safety and pharmacokinetics of a new biosimilar trastuzumab (HL02): a Phase I bioequivalence study in healthy Chinese menExpert Opinion on Biological Therapy2021
A Phase I Clinical Study Comparing the Tolerance, Immunogenicity, and Pharmacokinetics of Proposed Biosimilar BAT1806 and Reference Tocilizumab in Healthy Chinese MenFrontiers in Pharmacology2020
A randomized phase-I pharmacokinetic trial comparing the potential biosimilar tocilizumab (QX003S) with the reference product (Actemra) in Chinese healthy subjectsAnnals of Medicine2021
Safety and pharmacokinetics of a biosimilar of denosumab (KN012): Phase 1 and bioequivalence study in healthy Chinese subjectsExpert Opinion on Investigational Drugs2021
Efficacy and safety of follitropin alpha biosimilars compared to their reference product: a Meta-analysisGynecological Endocrinology2021
Economic evaluation of biosimilars for reimbursement purposes - what, when, how?Journal of Market Access & Health Policy2020
A randomized phase I pharmacokinetic trial comparing the potential biosimilar adalimumab (CinnoRA®) with the reference product (Humira®) in healthy volunteersExpert Opinion on Investigational Drugs2020
Analytical Similarity of a Proposed Biosimilar BVZ-BC to BevacizumabAnalytical Chemistry2020
Long-term Efficacy, Safety, and Immunogenicity of the Infliximab (IFX) Biosimilar, PF-06438179/GP1111, in Patients with Rheumatoid Arthritis After Switching from Reference IFX or Continuing Biosimilar Therapy: Week 54-78 Data From a Randomized, Double-Blind, Phase III TrialBioDrugs2020
Biosimilar Drug Development2020
Higher-Order Structure Comparison of a Proposed Biosimilar and the Innovator Biotherapeutic Trastuzumab using Circular Dichroism Coupled with Statistical AnalysisJournal of Applied Spectroscopy2020
Potential Cost-Savings From the Use of the Biosimilars in SlovakiaFrontiers in Public Health2020
A Phase I, Randomized, Single-Dose Study to Evaluate the Biosimilarity of QL1206 to Denosumab Among Chinese Healthy SubjectsFrontiers in Pharmacology2020
The Importance of Countering Biosimilar Disparagement and MisinformationBioDrugs2020
Tendering and biosimilars: what role for value-added services?Journal of Market Access & Health Policy2020
A Randomized, Double-Blind, Efficacy and Safety Study of PF-05280586 (a Rituximab Biosimilar) Compared with Rituximab Reference Product (MabThera) in Subjects with Previously Untreated CD20-Positive, Low-Tumor-Burden Follicular Lymphoma (LTB-FL)BioDrugs2020
A randomized, double-blind, single-dose study to evaluate the biosimilarity of QL1101 with bevacizumab in healthy male subjectsCancer Chemotherapy and Pharmacology2020
Etanercept biosimilar SB-4Expert Opinion on Biological Therapy2019
PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: a randomised, double-blind studyBritish Journal of Cancer2019